BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy

RAS Signaling in Colorectal Carcinomas through Alteration of RAS, RAF, NF1, and/or RASSF1A

(2015) Terje Ahlquist et al.   NEOPLASIA

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

(2011) N Knijn et al.   BRITISH JOURNAL OF CANCER

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

(2011) T Yokota et al.   BRITISH JOURNAL OF CANCER

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer

(2011) Jin Hyun Park et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer

(2011) Cecily P. Vaughn et al.   GENES CHROMOSOMES & CANCER

Impact ofKRASandBRAFGene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer

(2011) Timothy J. Price et al.   JOURNAL OF CLINICAL ONCOLOGY

High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice

(2010) D. Santini et al.   ANNALS OF ONCOLOGY

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients

(2010) A. Fariña-Sarasqueta et al.   ANNALS OF ONCOLOGY

Surgery for colorectal liver metastases

(2010) J N Primrose   BRITISH JOURNAL OF CANCER

Surgical management and outcomes of colorectal cancer liver metastases

(2010) E. J. A. Morris et al.   BRITISH JOURNAL OF SURGERY

Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

(2010) S. E. Baldus et al.   CLINICAL CANCER RESEARCH

PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

(2009) Y. He et al.   CLINICAL CANCER RESEARCH

KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

(2009) Susan D. Richman et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

(2009) Arnaud D. Roth et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

(2009) Gunnar Folprecht et al.   LANCET ONCOLOGY

BRAFMutation in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients

(2008) J. W. Tyner et al.   BLOOD

Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer

(2008) A. J. French et al.   CLINICAL CANCER RESEARCH

Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics

(2008) Guoren Deng et al.   EUROPEAN JOURNAL OF CANCER

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

(2008) S. Ogino et al.   GUT

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers

(2008) Ludovic Barault et al.   INTERNATIONAL JOURNAL OF CANCER